Brad Wideman has significant law firm and in-house leadership experience and focuses his practice on complex matters involving corporate governance, securities regulation, executive compensation, crisis management, financings and international M&A transactions. Brad's decade-long experience in the law departments of major companies provides him with valuable insight about the challenges faced by in-house lawyers and allows him to work collaboratively to address those challenges in cost-effective ways.

    He has represented public and private companies with mergers and acquisitions, capital formation, securities and corporate law, regulatory compliance, antitakeover matters, and shareholder engagement and activism. Brad has also assisted clients in managing internal investigations, as well as with the US Securities and Exchange Commission, the Financial Industry Regulatory Authority and stock exchange investigatory matters.

    Award Mouse thought multimedia interface book medal screen monitor

    Securities and Corporate Governance

    • Lead securities and corporate governance lawyer for two publicly traded companies.
    • Advised numerous other public and private companies on corporate governance best practices as well as on securities regulation.

    Executive Compensation

    • Advised numerous public companies and compensation committees regarding employment, compensation and severance arrangements for executive officers.
    • Lead in-house lawyer responsible for the compensation disclosures at two publicly traded companies.
    • Served as administrator of Gardner Denver’s global equity plan.
    • Responsible for director compensation and executive compensation matters on an interim basis at a publicly traded company.

    M&A Matters

    • Advised Mylan in its US$9.9 billion acquisition of Meda, its successful takeover defense against Teva’s US$40 billion hostile non-binding indication of interest, its proposal to acquire Perrigo in a transaction valued at approximately US$35 billion, its US$5.6 billion inversion acquisition of Abbott Laboratories’ non-US developed markets specialty and branded generics business.
    • Advised Gardner Denver’s exploration of strategic alternatives that resulted in a sale to a private equity firm for approximately US$4 billion and its US$207 million acquisition of Robuschi.

    Financing/Equity Matters

    • Advised Mylan in approximately US$40 billion of financing transactions, including, but not limited to, senior notes offerings, credit facilities, term loans, bridge loans, European bond offerings, accounts receivable securitization facilities and a commercial paper facility.
    • Counsel to various investment banks for approximately US$1.0 billion in bond offerings and an “at the market” offering program for a publicly traded real estate investment trust.
    • Advised multiple other public companies in approximately US$2.0 billion in aggregate debt.
    • Advised multiple start-up companies on venture capital raising transactions.

    Education

    • University of Missouri School of Law, J.D., 2005
    • University of Missouri, M.A., 2002
    • Westminster College, B.A., 2000

    Admissions

    • Missouri, 2005
    Award Mouse thought multimedia interface book medal screen monitor